<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02192723</url>
  </required_header>
  <id_info>
    <org_study_id>Project863</org_study_id>
    <nct_id>NCT02192723</nct_id>
  </id_info>
  <brief_title>A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia</brief_title>
  <official_title>Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing HuiLongGuan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing HuiLongGuan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and side effects of 6 commonly used
      antipsychotic drugs in the treatment of schizophrenia in a Chinese population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The relative effectiveness of second-generation (atypical) antipsychotic drugs as compared
      with that of older agents has been incompletely addressed, though newer agents are currently
      used far more commonly. The investigators compared a first-generation antipsychotic,
      perphenazine or haloperidol, with several newer drugs in a double-blind study.

      METHODS: A total of 550 patients with schizophrenia were recruited at 4 Chinese sites and
      randomly assigned to receive perphenazine (16 to 64 mg per day) or haloperidol(6 t0 20mg per
      day), olanzapine (5 to 20 mg per day), quetiapine (400 to 750 mg per day), aripiprazole (10
      to 30 mg per day) or risperidone (2 to 6.0 mg per day) for up to 8 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The Clinical Global Impression rating scales are commonly used measures of symptom severity, treatment response and the efficacy of treatments in treatment studies of patients with mental disorders</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale</measure>
    <time_frame>Baseline, 8 weeks</time_frame>
    <description>The UKU Side Effect Rating Scale is a comprehensive, clinician-rated scale, designed to assess the side effects in patients treated with psychotropic medications.</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">550</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Typical antipsychotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Haloperidol (6~20mg/day) and perphenazine (16~64mg/day) for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risperidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperidone, 2~6mg/day, twice day, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5~20mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quetiapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400~750mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Aripiprazole, 10~30mg/day, twice per day, 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ziprasidone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ziprasidone, 80~160mg/day, twice per day, 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Typical antipsychotic</intervention_name>
    <description>Haloperidol (6~20mg/day) and perphenazine (16~64mg/day), twice per day, 8 weeks</description>
    <arm_group_label>Typical antipsychotic</arm_group_label>
    <other_name>Haldol and Trilafon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>2~6mg/day, twice per day, 8 weeks</description>
    <arm_group_label>Risperidone</arm_group_label>
    <other_name>Risperdal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine, 400~750mg/day, twice per day, 8 weeks</description>
    <arm_group_label>Olanzapine</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine, 400～750mg/day, twice per day, 8 weeks</description>
    <arm_group_label>Quetiapine</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aripiprazole</intervention_name>
    <description>Aripiprazole, 10～30mg/day, twice per day, 8 weeks</description>
    <arm_group_label>Aripiprazole</arm_group_label>
    <other_name>Abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>Ziprasidone 80~160mg/day, twice per day, 8 weeks</description>
    <arm_group_label>Ziprasidone</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients' diagnoses is based on the results of the Structured Clinical Interview for
             DSM (SCID) using the criteria of the fourth edition of the Diagnostic and Statistical
             Manual (DSM-IV), physical exams and routine chemistry, and hematology laboratory
             tests. Attending-level psychiatrists will use a Chinese translation of the SCID to
             interview patients and their family members, who are given freedom to ask additional
             questions if respondents do not understand the standard probes.

          -  Patients must meet the following criteria: (1) diagnosis of schizophrenia; (2)
             duration of illness more than 2 years; (3) between 25 and 60 years of age; and (5)
             have NOT received antipsychotic medication for at least 1 month;(6) acute
             exacerbations of chronic inpatients.

          -  A complete medical history, electroencephalograms and electrocardiogram are obtained,
             and a physical examination and laboratory tests are performed at study entrance. None
             of the study participants have abnormal findings on these tests.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhi-Ren Wang, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Beijing HuiLongGuan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing HuiLongGuan Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100096</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>July 10, 2016</last_update_submitted>
  <last_update_submitted_qc>July 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing HuiLongGuan Hospital</investigator_affiliation>
    <investigator_full_name>Xiang Yang Zhang</investigator_full_name>
    <investigator_title>Director, the Research Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Antipsychotic Agents</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

